Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Noveko announces new appointments

This article was originally published in Scrip

Executive Summary

Noveko International has announced two new appointments: Barry McDonald as consultant for projects requiring regulatory approval, and Alain Bolduc as president and general manager of the Noveko Inc subsidiary. Mr McDonald most recently served as interim president and CEO of TS03; before that he was executive director for the US consulting firm The Sage Group. As consultant at Noveko, Mr McDonald will aid the company in its market development efforts across Europe and Asia. Mr Bolduc currently holds the position of chief operating officer of Noveko and will take the role of president and general manager of the subsidiary in lieu of José Larrea. Mr Bolduc will lead the subsidiary in the development and marketing of the company's flagship products based on its patented antimicrobial filtration technology.

You may also be interested in...



How to leverage India: Five up-and-coming domestic players

The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.

Active Biotech appoints CSO

The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.

Affimed appoints new chief commercial officer

Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).

Topics

UsernamePublicRestriction

Register

SC032121

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel